A Long CBD Half-Life After One Fed Dose Was Not Evidence of Chronic Safety
A phase-one study found prolonged CBD persistence after a single dose taken following a high-fat meal. Its reassuring short-term tolerability findings did not establish safety during repeated dosing or a reliable personal elimination deadline.
Three small dose cohorts
Twenty-four healthy volunteers entered three sequential cohorts. Each cohort included six participants receiving CBD and two receiving placebo. The active doses were 5, 10 or 20 mg/kg in a lipid-based oral formulation after a high-fat meal.
Plasma was sampled through eight days. Those repeated samples describe concentration over time in a small group; they are not additional independent participants. The design also lacked a matched fasting condition, so it could not independently quantify a food effect.
Peak timing and terminal persistence were different
Median time to maximum plasma concentration was approximately four hours across cohorts. Exposure increased with dose, while the terminal elimination half-life was approximately 70 hours.
A terminal half-life describes a fitted portion of the concentration curve. It does not mean that effects last 70 hours, that half the dose remains in plasma at that point, or that every individual will test negative on a fixed later date.
What the safety observations can support
No severe or serious adverse events occurred in this single-dose experiment, and clinical assessments did not identify a new safety concern under the protocol. Headache and diarrhea were among the reported events.
Healthy volunteers receiving one dose do not represent patients using CBD repeatedly with other medicines. Accumulation, drug interactions, formulation differences and individual variability require separate evidence. The study offers useful single-dose pharmacokinetics and short-term tolerability data, rather than a general guarantee of safe chronic use.
Related: Why treatment outcomes require attention to study design.
Primary research
A Phase 1, Randomised, Placebo-Controlled, Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Cannabidiol in Fed Healthy Volunteers. European Journal of Drug Metabolism and Pharmacokinetics (2020).
